Anatomical Therapeutic Chemical • L01EH03 • tucatinib

L Antineoplastic and immunomodulating agents

L01 Antineoplastic agents

L01A Alkylating agents

L01B Antimetabolites

L01C Plant alkaloids and other natural products

L01D Cytotoxic antibiotics and related substances

L01E Protein kinase inhibitors

L01EA BCR-ABL tyrosine kinase inhibitors

L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

L01EC B-raf serine-threonine kinase (BRAF) inhibitors

L01ED Anaplastic lymphoma kinase (ALK) inhibitors

L01EE Mitogen-activated protein kinase (MEK) inhibitors

L01EF Cyclin-dependent kinase (CDK) inhibitors

L01EG Mammalian target of rapamycin (MTOR) kinase inhibitors

L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors

L01EH01 lapatinib Indicated for: cancer

L01EH02 neratinib Indicated for: breast cancer

L01EH03 tucatinib Indicated for: HER2-positive breast cancer

L01EJ Janus-associated kinase (JAK) inhibitors

L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors

L01EL Bruton's tyrosine kinase (BTK) inhibitors

L01EM Phosphatidylinositol-3-kinase (PI3K) inhibitors

L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors

L01EP Cellular-mesenchymal-epithelial transition factor (c-met) kinase inhibitors

L01EX Other protein kinase inhibitors

L01F Monoclonal antibodies and antibody drug conjugates

L01X Other antineoplastic agents

L02 Endocrine therapy

L03 Immunostimulants

L04 Immunosuppressants